Weiner, Michael W.Veitch, Dallas P.Miller, Melanie J.Aisen, Paul S.Albala, BruceBeckett, Laurel A.Green, Robert C.Harvey, DanielleJack, Clifford R., Jr.Jagust, WilliamLandau, Susan M.Morris, John C.Nosheny, RachelOkonkwo, Ozioma C.Perrin, Richard J.Petersen, Ronald C.Rivera-Mindt, MonicaSaykin, Andrew J.Shaw, Leslie M.Toga, Arthur W.Tosun, DuyguTrojanowski, John Q.Alzheimer's Disease Neuroimaging Initiative2023-11-202023-11-202023Weiner MW, Veitch DP, Miller MJ, et al. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimers Dement. 2023;19(1):307-317. doi:10.1002/alz.12797https://hdl.handle.net/1805/37144Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.en-USAttribution-NonCommercial 4.0 InternationalAlzheimer's diseaseAmyloidCerebrovascular diseaseDigital biomarkersGeneralizabilityMild cognitive impairmentPlasma biomarkersTauUnderrepresented populationsIncreasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4Article